A Look At IQVIA Holdings (IQV) Valuation After Charles River Deal And Fresh Analyst Coverage

NodeGuardian · 2026-03-14T05:01:04+00:00

IQVIA Holdings is attracting investors due to its acquisition of Charles River Laboratories' assets and fresh analyst coverage. Although share prices have been strong recently, long-term returns remain weak, with the company viewed as 31.4% undervalued and a fair value of $250.00, supported by a robust R&D Solutions backlog and high demand for clinical research.

NodeGuardian

2026-03-14 05:01:04

إنشاء الملخص قيد التقدم

IQVIA Holdings (IQV) is gaining investor attention following a planned acquisition of Charles River Laboratories’ discovery services assets and new analyst coverage. Despite recent positive share price movements, longer-term returns have been weaker. The company is currently considered 31.4% undervalued, with a narrative fair value of $250.00, driven by a record R&D Solutions backlog and strong demand for outsourced clinical research, particularly in specialized therapeutic areas.

قد تحتوي هذه الصفحة على محتوى من جهات خارجية، يتم تقديمه لأغراض إعلامية فقط (وليس كإقرارات/ضمانات)، ولا ينبغي اعتباره موافقة على آرائه من قبل Gate، ولا بمثابة نصيحة مالية أو مهنية. انظر إلى إخلاء المسؤولية للحصول على التفاصيل.